This study evaluates the efficacy and safety of SNS-101, a pH-selective antibody targeting the V-domain Ig suppressor of T cell activation (VISTA), in enhancing anti-PD-1 therapy responses. The research investigates how SNS-101 modulates immune checkpoints to improve cancer immunotherapy outcomes.
SNS-101 demonstrated favorable pharmacokinetics and safety profiles, effectively enhancing the response to PD-1 blockade in tumor models. The combination therapy led to significant tumor growth inhibition, suggesting that pH-selective VISTA inhibition can potentiate anti-PD-1 immunotherapy.
The study utilized human VISTA Knockin and BRGSF-HIS mouse models developed in collaboration with genOway. These models express human VISTA, allowing for the assessment of SNS-101's efficacy and safety in a humanized immune system context.
Cancer immunotherapy, Immune checkpoint inhibition, VISTA targeting, PD-1 blockade, Tumor immunology
Humanized Knockin model, BRGSF-HIS mouse model, pH-selective antibody, Immune checkpoint modulation, Combination therapy evaluation
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
